-
公开(公告)号：WO2019232433A2
公开(公告)日：2019-12-05
申请号：PCT/US2019/034992
申请日：2019-05-31
发明人： PAZOLLI, Ermira , BUONAMICI, Silvia , PALACINO, James , SEILER, Michael , ZHU, Ping , BARRY, Evan , YU, Lihua
IPC分类号： A61K31/496 , A61P35/00 , A61P35/02 , A61P43/00
摘要： This disclosure relates to methods for the treatment of neoplastic disorders by administering Compound 1, or a pharmaceutically acceptably salt thereof, on its own and/or as part of a conjugate or composition, and inducing production of at least one neoantigen.
-
公开(公告)号：WO2018098251A1
公开(公告)日：2018-05-31
申请号：PCT/US2017/062978
申请日：2017-11-22
申请人： EISAI R&D MANAGEMENT CO., LTD. , BOCK, Mark , HAO, Ming-Hong , KORPAL, Manav , NYAVANANDI, Vijay Kumar , PUYANG, Xiaoling , SAMAJDAR, Susanta , SMITH, Peter Gerard , WANG, John , ZHENG, Guo Zhu , ZHU, Ping , MITCHELL, Lorna Helen , LARSEN, Nicholas , RIOUX, Nathalie
发明人： BOCK, Mark , HAO, Ming-Hong , KORPAL, Manav , NYAVANANDI, Vijay Kumar , PUYANG, Xiaoling , SAMAJDAR, Susanta , SMITH, Peter Gerard , WANG, John , ZHENG, Guo Zhu , ZHU, Ping , MITCHELL, Lorna Helen , LARSEN, Nicholas , RIOUX, Nathalie
IPC分类号： C07D209/08 , A61P35/00
摘要： Disclosed herein are compounds, or pharmaceutically acceptable salts thereof, and methods of using the compounds for treating breast cancer by administration to a subject in need thereof a therapeutically effective amount of the compounds or pharmaceutically acceptable salts thereof. The breast cancer may be an ER-positive breast cancer and/or the subject in need of treatment may express a mutant ER-α protein.
-
公开(公告)号：WO2019232449A1
公开(公告)日：2019-12-05
申请号：PCT/US2019/035015
申请日：2019-05-31
发明人： PAZOLLI, Ermira , BUONAMICI, Silvia , SAMARAKOON, Thiwanka , PRAJAPATI, Sudeep , FISHKIN, Nathan , PALACINO, James , SEILER, Michael , ZHU, Ping , COOK, Andrew , SMITH, Peter , LIU, Xiang , ELLERY, Shelby , REYNOLDS, Dominic , YU, Lihua , WU, Zhenhua , PENG, Shouyong , CALANDRA, Nicholas , SHEEHAN, Megan , XIAO, Yonghong
摘要： Linker-drug compounds and antibody-drug conjugates that bind to human oncology targets are disclosed. The linker-drug compounds and antibody-drug conjugates comprise a splicing modulator drug moiety. The disclosure further relates to methods and compositions for use in the treatment of neoplastic disorders by administering the antibody-drug conjugates provided herein. In an embodiment, the splicing modulator comprises a pladienolide or a pladienolide derivative.
-
公开(公告)号：WO2019089641A1
公开(公告)日：2019-05-09
申请号：PCT/US2018/058277
申请日：2018-10-30
申请人： EISAI R&D MANAGEMENT CO., LTD. , AIRD, Daniel , CORSON, Laura , ZHU, Ping , WARMUTH, Markus , BUONAMICI, Silvia , SMITH, Peter Gerard , FEKKES, Peter
发明人： AIRD, Daniel , CORSON, Laura , ZHU, Ping , WARMUTH, Markus , BUONAMICI, Silvia , SMITH, Peter Gerard , FEKKES, Peter
摘要： The present disclosure provides pharmaceutical combinations comprising at least one spliceosome modulator and at least one inhibitor chosen from BCL2, BCL2/BCLxL, and BCLxL inhibitors. Also provided are methods of treating cancer comprising administering a therapeutically effective amount of at least one spliceosome modulator and a therapeutically effective amount of at least one inhibitor chosen from BCL2, BCL2/BCLxL, and BCLxL inhibitors.
-
公开(公告)号：WO2018098305A1
公开(公告)日：2018-05-31
申请号：PCT/US2017/063047
申请日：2017-11-22
申请人： EISAI R&D MANAGEMENT CO., LTD. , BOCK, Mark , HAO, Ming-Hong , KORPAL, Manav , NYAVANANDI, Vijay Kumar , PUYANG, Xiaoling , SAMAJDAR, Susanta , SMITH, Peter Gerard , WANG, John , ZHENG, Guo Zhu , ZHU, Ping , MITCHELL, Lorna Helen , LARSEN, Nicholas , RIOUX, Nathalie , PRAJAPATI, Sudeep , REYNOLDS, Dominic , O'SHEA, Morgan , SAMARAKOON, Thiwanka
发明人： BOCK, Mark , HAO, Ming-Hong , KORPAL, Manav , NYAVANANDI, Vijay Kumar , PUYANG, Xiaoling , SAMAJDAR, Susanta , SMITH, Peter Gerard , WANG, John , ZHENG, Guo Zhu , ZHU, Ping , MITCHELL, Lorna Helen , LARSEN, Nicholas , RIOUX, Nathalie , PRAJAPATI, Sudeep , REYNOLDS, Dominic , O'SHEA, Morgan , SAMARAKOON, Thiwanka
IPC分类号： C07D403/12 , C07D401/14 , C07D231/56 , C07D401/06 , A61P35/00 , A61K31/416
摘要： Disclosed herein are compounds, or pharmaceutically acceptable salts thereof, and methods of using the compounds for treating breast cancer by administration to a subject in need thereof a therapeutically effective amount of the compounds or pharmaceutically acceptable salts thereof. The breast cancer may be an ER-positive breast cancer and/or the subject in need of treatment may express a mutant ER-α protein.
-
公开(公告)号：WO2021248005A1
公开(公告)日：2021-12-09
申请号：PCT/US2021/035913
申请日：2021-06-04
发明人： HENRY, Ryan , SAMARAKOON, Thiwanka , FISHKIN, Nathan , ZHU, Ping , PAZOLLI, Ermira , PALACINO, James , ALMAGRO, Juan
IPC分类号： C07K16/28 , A61K47/68 , A61P35/02 , C07D405/06 , C07D405/14 , C07D407/06 , A61K39/00 , A61K2039/505 , A61K47/6803 , A61K47/6849 , A61K47/6867 , A61K47/6889 , C07K16/2878 , C07K2317/565
摘要： Antibodies, antigen-binding fragments, and conjugates (e.g., antibody-drug conjugates (ADCs) such as those comprising a splicing modulator) that bind to BCMA are disclosed. The disclosure further relates to methods and compositions for use in the treatment of cancer by administering a composition provided herein.
-
公开(公告)号：WO2017040526A2
公开(公告)日：2017-03-09
申请号：PCT/US2016/049490
申请日：2016-08-30
申请人： EISAI R&D MANAGEMENT CO., LTD. , YU, Lihua , LIM, Kian, Huat , FEALA, Jacob, D. , BUONAMICI, Silvia , MIZUI, Yoshiharu , SMITH, Peter, G. , ZHU, Ping , PARK, Eunice, Sun , SEILER, Michael, W. , FEKKES, Marco, Peter
发明人： YU, Lihua , LIM, Kian, Huat , FEALA, Jacob, D. , BUONAMICI, Silvia , MIZUI, Yoshiharu , SMITH, Peter, G. , ZHU, Ping , PARK, Eunice, Sun , SEILER, Michael, W. , FEKKES, Marco, Peter
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6886 , C12Q2600/106 , C12Q2600/158
摘要： Splice variants associated with neomorphic SF3B1 mutations are described herein. This application also relates to methods of detecting the described splice variants, and uses for diagnosing cancer, evaluating modulators of SF3B1, and methods of treating cancer associated with mutations in SF3B 1.
摘要翻译： 与新型SF3B1突变相关的剪接变体在本文中描述。 本申请还涉及检测所述剪接变体的方法，以及用于诊断癌症，评估SF3B1调节剂的用途以及治疗与SF3B1突变有关的癌症的方法。
-
公开(公告)号：WO2019232449A9
公开(公告)日：2019-12-05
申请号：PCT/US2019/035015
申请日：2019-05-31
发明人： PAZOLLI, Ermira , BUONAMICI, Silvia , SAMARAKOON, Thiwanka , PRAJAPATI, Sudeep , FISHKIN, Nathan , PALACINO, James , SEILER, Michael , ZHU, Ping , COOK, Andrew , SMITH, Peter , LIU, Xiang , ELLERY, Shelby , REYNOLDS, Dominic , YU, Lihua , WU, Zhenhua , PENG, Shouyong , CALANDRA, Nicholas , SHEEHAN, Megan , XIAO, Yonghong
摘要： Linker-drug compounds and antibody-drug conjugates that bind to human oncology targets are disclosed. The linker-drug compounds and antibody-drug conjugates comprise a splicing modulator drug moiety. The disclosure further relates to methods and compositions for use in the treatment of neoplastic disorders by administering the antibody-drug conjugates provided herein. In an embodiment, the splicing modulator comprises a pladienolide or a pladienolide derivative.
-
公开(公告)号：WO2019232433A3
公开(公告)日：2019-12-05
申请号：PCT/US2019/034992
申请日：2019-05-31
发明人： PAZOLLI, Ermira , BUONAMICI, Silvia , PALACINO, James , SEILER, Michael , ZHU, Ping , BARRY, Evan , YU, Lihua
摘要： This disclosure relates to methods for the treatment of neoplastic disorders by administering Compound 1, or a pharmaceutically acceptably salt thereof, on its own and/or as part of a conjugate or composition, and inducing production of at least one neoantigen.
-
公开(公告)号：WO2016196346A1
公开(公告)日：2016-12-08
申请号：PCT/US2016/034782
申请日：2016-05-27
发明人： BOCK, Mark , HAO, Ming-Hong , KORPAL, Manav , NYAVANANDI, Vijay Kumar , PUYANG, Xiaoling , SAMAJDAR, Susanta , SMITH, Peter Gerard , WANG, John , ZHENG, Guo Zhu , ZHU, Ping
IPC分类号： A61K31/4439 , C07D317/02 , C07D317/06 , C07D487/04
CPC分类号： C07D231/56 , C07D401/06 , C07D401/14 , C07D403/06 , C07D403/12 , C07D471/14
摘要： Disclosed herein are compounds, or pharmaceutically acceptable salts thereof, and methods of using the compounds for treating breast cancer by administration to a subject in need thereof a therapeutically effective amount of the compounds or pharmaceutically acceptable salts thereof. The breast cancer may be an ER-positive breast cancer and/or the subject in need of treatment may express a mutant ER-α protein.
摘要翻译： 本文公开了化合物或其药学上可接受的盐，以及通过向有需要的受试者施用治疗有效量的化合物或其药学上可接受的盐来使用该化合物治疗乳腺癌的方法。 乳腺癌可能是ER阳性乳腺癌，和/或需要治疗的受试者可以表达突变型ER-α蛋白。
-
-
-
-
-
-
-
-
-
搜索结果
12 条记录 (耗时 0.014 秒)
